Drug intelligence / Profile preview

ECP-066

Development stage: Preclinical
Lead developer: ECP

Overview

**ECP-066** is an ECP Pharma preclinical drug-development candidate for **amnestic mild cognitive impairment**. ECP has not publicly disclosed the candidate's active ingredient, molecular target, modality, route of administration, dosage form, or precise mechanism of action. ECP states that its aMCI research program focuses on neurological changes occurring before dementia and Alzheimer's disease rather than directly targeting amyloid plaques. ([ecppharma.com](https://www.ecppharma.com/pipeline/))

Beyond the preview

Go deeper on ECP-066.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECP-066.

Explore the full profile